Literature DB >> 26603166

Subclinical intestinal inflammation in chronic granulomatous disease patients.

Arnon Broides1,2, Orli Sagi3,4, Vered Pinsk5,4, Jacov Levy6,4, Baruch Yerushalmi5,4.   

Abstract

Chronic granulomatous disease is a primary immunodeficiency caused by impaired neutrophil production of reactive oxygen species. Non-infectious colitis is common in chronic granulomatous disease, and high levels of antimicrobial antibodies that are associated with Crohn's disease are common even without colitis. Fecal calprotectin concentration is a marker for intestinal inflammation. We sought to determine whether subclinical intestinal inflammation occurs in asymptomatic chronic granulomatous disease patients. Asymptomatic chronic granulomatous disease patients without overt gastrointestinal symptoms suggestive of colitis at the time of enrollment were studied for fecal calprotectin concentration, antibodies associated with Crohn's disease and systemic inflammatory markers. Eight patients were included, aged 54-176 months. In 7/8 (87.5 %) fecal calprotectin concentration was normal (<50) and elevated (137 mg/kg) in only one patient. This patient later developed colitis. In 7/8 (87.5 %) anti-Saccharomyces cerevisiae antibody was positive. C-reactive protein, albumin, complete blood count and p-anti-neutrophil cytoplasmic antibody were normal in all 8 patients. Subclinical colitis is not evident in most asymptomatic chronic granulomatous disease patients; however, in some patients, fecal calprotectin concentration may be elevated, possibly indicating the presence of subclinical colitis and predicting the occurrence of clinically relevant colitis. Serum anti-Saccharomyces cerevisiae antibody concentrations do not seem to correlate with fecal calprotectin concentration in asymptomatic chronic granulomatous disease patients.

Entities:  

Keywords:  Calprotectin; Chronic granulomatous disease; Colitis; Inflammatory bowel disease

Mesh:

Substances:

Year:  2016        PMID: 26603166     DOI: 10.1007/s12026-015-8733-2

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  22 in total

1.  Restoration of anti-Aspergillus defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent.

Authors:  Matteo Bianchi; Maria J Niemiec; Ulrich Siler; Constantin F Urban; Janine Reichenbach
Journal:  J Allergy Clin Immunol       Date:  2011-03-03       Impact factor: 10.793

2.  High levels of Crohn's disease-associated anti-microbial antibodies are present and independent of colitis in chronic granulomatous disease.

Authors:  Joyce E Yu; Suk See De Ravin; Gulbu Uzel; Carol Landers; Stephan Targan; Harry L Malech; Steven M Holland; Wenqing Cao; Noam Harpaz; Lloyd Mayer; Charlotte Cunningham-Rundles
Journal:  Clin Immunol       Date:  2010-10-16       Impact factor: 3.969

3.  Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study.

Authors:  Baldassarre Martire; Roberto Rondelli; Annarosa Soresina; Claudio Pignata; Teresa Broccoletti; Andrea Finocchi; Paolo Rossi; Marco Gattorno; Marco Rabusin; Chiara Azzari; Rosa M Dellepiane; Maria C Pietrogrande; Antonino Trizzino; Paolo Di Bartolomeo; Silvana Martino; Luigi Carpino; Fausto Cossu; Franco Locatelli; Rita Maccario; Paolo Pierani; Maria C Putti; Achille Stabile; Luigi D Notarangelo; Alberto G Ugazio; Alessandro Plebani; Domenico De Mattia
Journal:  Clin Immunol       Date:  2007-11-26       Impact factor: 3.969

4.  Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease.

Authors:  C B Foster; T Lehrnbecher; F Mol; S M Steinberg; D J Venzon; T J Walsh; D Noack; J Rae; J A Winkelstein; J T Curnutte; S J Chanock
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

5.  Gastrointestinal involvement in chronic granulomatous disease.

Authors:  Beatriz E Marciano; Sergio D Rosenzweig; David E Kleiner; Victoria L Anderson; Dirk N Darnell; Sandra Anaya-O'Brien; Dianne M Hilligoss; Harry L Malech; John I Gallin; Steven M Holland
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

6.  IBD and IBD mimicking enterocolitis in children younger than 2 years of age.

Authors:  Z Cannioto; I Berti; S Martelossi; I Bruno; N Giurici; S Crovella; A Ventura
Journal:  Eur J Pediatr       Date:  2008-06-11       Impact factor: 3.183

7.  Chronic granulomatous disease caused by a deficiency in p47(phox) mimicking Crohn's disease.

Authors:  Jeannie S Huang; Deborah Noack; Julie Rae; Beverly A Ellis; Robert Newbury; Alice L Pong; Joel E Lavine; John T Curnutte; John Bastian
Journal:  Clin Gastroenterol Hepatol       Date:  2004-08       Impact factor: 11.382

Review 8.  Current concepts of hyperinflammation in chronic granulomatous disease.

Authors:  Nikolaus Rieber; Andreas Hector; Taco Kuijpers; Dirk Roos; Dominik Hartl
Journal:  Clin Dev Immunol       Date:  2011-07-25

Review 9.  The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis.

Authors:  Paul Henderson; Niall H Anderson; David C Wilson
Journal:  Am J Gastroenterol       Date:  2013-05-14       Impact factor: 12.045

10.  Chronic granulomatous disease: the European experience.

Authors:  J Merlijn van den Berg; Elsbeth van Koppen; Anders Ahlin; Bernd H Belohradsky; Ewa Bernatowska; Lucien Corbeel; Teresa Español; Alain Fischer; Magdalena Kurenko-Deptuch; Richard Mouy; Theoni Petropoulou; Joachim Roesler; Reinhard Seger; Marie-José Stasia; Niels H Valerius; Ron S Weening; Baruch Wolach; Dirk Roos; Taco W Kuijpers
Journal:  PLoS One       Date:  2009-04-21       Impact factor: 3.240

View more
  5 in total

Review 1.  The Treatment of Inflammatory Bowel Disease in Patients with Selected Primary Immunodeficiencies.

Authors:  Dror S Shouval; Matthew Kowalik; Scott B Snapper
Journal:  J Clin Immunol       Date:  2018-06-29       Impact factor: 8.317

Review 2.  Inflammatory Bowel Disease in Primary Immunodeficiencies.

Authors:  Judith R Kelsen; Kathleen E Sullivan
Journal:  Curr Allergy Asthma Rep       Date:  2017-08       Impact factor: 4.806

3.  Needs for Increased Awareness of Gastrointestinal Manifestations in Patients With Human Inborn Errors of Immunity.

Authors:  Eun Sil Kim; Dongsub Kim; Yoonsun Yoon; Yiyoung Kwon; Sangwoo Park; Jihyun Kim; Kang Mo Ahn; Soomin Ahn; Yon Ho Choe; Yae-Jean Kim; Mi Jin Kim
Journal:  Front Immunol       Date:  2021-08-12       Impact factor: 7.561

4.  Perianal Disease and Granulomas: Think Out of the Box….

Authors:  Ana Reis-Melo; Maria do Céu Espinheira; Isabel Pinto-Pais; Artur Bonito Vitor; Jacinta Bustamante; Eunice Trindade
Journal:  GE Port J Gastroenterol       Date:  2019-10-01

Review 5.  Recent advances in understanding and treating chronic granulomatous disease.

Authors:  Andrew Gennery
Journal:  F1000Res       Date:  2017-08-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.